Nonsense mutation Duchenne muscular dystrophy (nmDMD) patients living in the European Union may soon experience relief from their condition due to the European Commission granting PTC Therapeutics, Inc. conditional marketing for Translarna™ (ataluren). PTC Therapeutics may now market Translarna in the 28 Member States of…
PTC Therapeutics’ Translarna for nmDMD is Conditionally Approved in European Union
Recent Posts
- Trial tests fever-inducing device as potential treatment for ALS
- FDA puts experimental T-cell treatment for ALS on fast track
- Guest Voice: What it means to be an ALS caregiver
- ALS Nexus 2026: Experimental therapy shows early promise in SOD1-ALS
- Finding meaning together in life after 16 years with ALS